Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease  
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2014

Scoped as part of Batch 37

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: 01 January 2100

Project Team

Associate Director: TBC
Communications manager: TBC
Project manager:


Technical Advisor: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
19 December 2014

Please note that following on from information received from the company, this appraisal will be rescheduled to align with the commercial availability of the product within the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual